Arrowstreet Capital
LRMR icon

Arrowstreet Capital’s Larimar Therapeutics LRMR Stock Holding History

Arrowstreet Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-920
Closed -$55K – 1827
2018
Q4 		$55K Buy
+920
New +$90.8K ﹤0.01% 1316

Other funds holding LRMR

AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Arrowstreet Capital's LRMR Position: Q1 2019 in Review

Arrowstreet Capital sold out of Larimar Therapeutics (LRMR) in Q1 2019, closing a stake of 920 shares — an estimated $55K sold.

Arrowstreet Capital first reported a position in LRMR in Q4 2018 and held it in 1 quarter. The position peaked at $55K in Q4 2018. 85 funds tracked by Wall St. Rank hold LRMR as of Q1 2019.

  • Arrowstreet Capital reported no remaining Larimar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Arrowstreet Capital sold 920 Larimar Therapeutics shares in Q1 2019, an estimated $55K.
  • Arrowstreet Capital first reported a position in Larimar Therapeutics in Q4 2018 and held it in 1 quarter.
  • Arrowstreet Capital's Larimar Therapeutics position peaked at $55K in Q4 2018.
  • 85 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2019.

Based on Arrowstreet Capital's 13F filing for Q1 2019, filed 15 May 2019.